Mounjaro Heart Health: Beyond the Scale—Weight Loss, Your Heart, Liver, and Kidneys

Mounjaro heart health is more nuanced than the headline claims: tirzepatide has cardiovascular evidence showing non-inferiority to another GLP-1 medicine in people with type 2 diabetes and established cardiovascular disease, but it is not licensed in the UK for heart protection, and that evidence does not prove superiority or general heart protection.

The number on the scales is the easiest thing to measure and the least interesting thing about weight loss. What matters clinically is what happens to blood pressure, blood glucose, blood lipids, liver fat, the liver and the kidneys, especially for adults in the UK considering weight management treatment and trying to judge whether a medicine may also affect cardiovascular or wider organ health.

There is now a substantial body of trial evidence on exactly that, and it is widely misreported. Findings are routinely attributed to the wrong medicine, lifted out of the population they were studied in, and described as organ protection when the trial tested something narrower. That matters if you have, or may be at risk of, cardiovascular disease, kidney or liver conditions, or type 2 diabetes, because expectations about direct heart, kidney or liver benefit can influence treatment choices, suitability and monitoring.

This page sets out what has actually been shown, in whom, and with which treatment. It covers weight loss effects on blood pressure, glucose and lipids; liver fat and organ health; cardiovascular outcome trials for semaglutide and tirzepatide; kidney and liver trial evidence; UK licensing positions; the clinical implications; and the common misconceptions that make these medicines sound broader in benefit than the evidence supports.

Key things to know

• Weight loss itself improves blood pressure, blood glucose, blood fats and liver fat for many people.
• Several large outcome trials have tested cardiovascular, kidney and liver endpoints, but they do not all apply to the same medicine.
• The kidney and phase 3 liver evidence comes from semaglutide trials, not tirzepatide.
• Tirzepatide's cardiovascular trial tested non-inferiority against another medicine, which is a different question from proving protection.
• Semaglutide (Wegovy) is licensed in the UK for cardiovascular risk reduction in certain adults with established cardiovascular disease and overweight or obesity. Tirzepatide (Mounjaro) is not currently licensed in the UK specifically for cardiovascular risk reduction. Neither medicine is licensed in the UK specifically for kidney or liver disease.
• Trial findings in a specific population do not automatically apply to someone outside it.
• Treatment suitability depends on an individual clinical assessment.

Start with what weight loss does on its own

Before any medicine enters the picture, losing weight changes several things that matter for heart health.

Blood pressure tends to fall. Blood sugar control improves, sometimes substantially, and for some people improved blood sugar control means steadier blood sugar as prediabetes moves back towards normal range. Blood fats improve. Fat stored in and around the liver reduces. Sleep apnoea often improves. Reducing excess weight also lowers cardiac workload. Joint loading reduces, which matters for mobility.

Even relatively modest weight loss can improve several cardiometabolic measures, while greater weight loss may bring additional benefits.

Any discussion of what a medicine does for organ health sits on top of this. Much of the benefit seen in trials follows from the weight loss and the metabolic changes that come with it, and medicines such as Mounjaro may also support weight reduction by reducing appetite and food cravings. Better weight and blood sugar control can also lower the risk of progression to type 2 diabetes.

What the heart trials actually tested

This is where attribution matters most, because two medicines are usually discussed as one.

The semaglutide evidence

SELECT enrolled more than 17,000 people with established cardiovascular disease and overweight or obesity, without diabetes. Semaglutide reduced the combined endpoint of cardiovascular death, non-fatal heart attack and non-fatal stroke by around 20% compared with placebo.

That is the most definitive cardiovascular finding in this field, and the population matters: people who already had cardiovascular disease.

The tirzepatide evidence

SURPASS-CVOT enrolled more than 13,000 people with type 2 diabetes and established atherosclerotic cardiovascular disease. It compared tirzepatide, sold as Mounjaro, against dulaglutide, another GLP-1 medicine, rather than against placebo. This trial addressed major adverse cardiovascular events in diabetes, not broad heart protection claims.

Tirzepatide was non-inferior to dulaglutide for the combined endpoint of cardiovascular death, non-fatal heart attack and non-fatal stroke. The result directionally favoured tirzepatide but did not demonstrate superiority. All-cause mortality was 16% lower with tirzepatide than with dulaglutide (HR 0.84, 95% CI 0.75–0.94), although this secondary finding was not adjusted for multiplicity and should not be interpreted as proof of a mortality benefit.

This is an important distinction that is frequently lost. Non-inferiority against an active comparator tells you the medicine is not worse than an established treatment. It is not the same as showing that it protects the heart relative to no treatment, even with a generally favorable cardiovascular profile for cardiovascular risk factor management.

Heart failure

SUMMIT studied 731 people with obesity and heart failure with preserved ejection fraction. Tirzepatide reduced the combined endpoint of cardiovascular death or worsening heart failure from 15.3% to 9.9%, and the trial showed a 38% relative reduction in worsening heart failure events.

That is a genuine finding in a genuinely difficult condition. Clinical indicators in this population also showed lower systolic blood pressure on tirzepatide, which matters because high blood pressure can add to cardiovascular risk. It is also a specific population: people who already had heart failure of a particular type alongside obesity.

Some people may see an initial rise in resting heart rate with tirzepatide, so these results should be interpreted with appropriate monitoring.

What this adds up to

Semaglutide currently has the broader and more mature cardiovascular outcome evidence. Tirzepatide has a non-inferiority result in diabetes with established cardiovascular disease, and a positive result in obesity-related heart failure, and it also appears to lower blood pressure, with dose-dependent effects reported in studies.

There is no head-to-head trial showing that either is better than the other for preventing heart attacks, strokes or cardiovascular death, and part of the interest in tirzepatide for heart health comes from broader risk-factor changes such as lower systemic inflammation and blood pressure. SURPASS-CVOT found an 8% lower rate of the combined cardiovascular endpoint of cardiovascular death, non-fatal heart attack and non-fatal stroke compared with dulaglutide, but it did not demonstrate superiority for this endpoint.

Kidneys: whose evidence is this?

The dedicated kidney outcome trial in this field is FLOW, and it studied semaglutide.

It enrolled people with type 2 diabetes and chronic kidney disease. Major kidney disease events occurred less frequently with semaglutide than with placebo, giving around a 24% lower relative risk of the primary outcome, with benefits also seen on secondary endpoints.

There is no equivalent dedicated kidney outcome trial for tirzepatide. A secondary analysis of SUMMIT reported effects on markers of cardiovascular and kidney organ damage in that heart failure population, which is suggestive rather than definitive. It may also slow eGFR decline in some high cardiovascular risk patients, but that is not the same as dedicated kidney outcome evidence.

So if you read that these medicines protect the kidneys, the evidence being referred to is almost certainly FLOW, in people with type 2 diabetes and existing chronic kidney disease, with kidney function monitoring still part of routine clinical follow-up.

Liver: an emerging picture

Liver health can improve when fat stored in the liver falls with weight loss, and that is not in dispute. The clinical question is whether treatment changes the disease itself.

The furthest advanced evidence here is ESSENCE, a phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis with moderate fibrosis, which reported histological findings at an interim analysis. Histology means looking at liver tissue rather than at a blood test or a scan. Earlier studies have also reported improvements in liver enzymes such as ALT, although enzyme changes alone do not establish improvement in liver fibrosis or long-term liver outcomes.

Tirzepatide has been studied in this area, but at an earlier phase.At 52 weeks, MASH resolution without worsening of fibrosis occurred in 44%, 56% and 62% of participants receiving 5 mg, 10 mg and 15 mg of tirzepatide, respectively, compared with 10% with placebo. The findings are promising, but this was a phase 2 study and longer-term evidence is still needed.

Either way, liver disease is not a licensed indication for these medicines in the UK, and anyone with known liver disease needs to be managed on its own terms rather than assumed to be covered by weight treatment.

The licensing position, and why it matters

In the UK, licensing depends on the specific medicine and indication. Mounjaro (tirzepatide) is licensed for type 2 diabetes and weight management, while Wegovy (semaglutide) is also licensed for cardiovascular risk reduction in certain adults with established cardiovascular disease and overweight or obesity. Neither medicine is currently licensed specifically to treat chronic kidney disease or liver disease.

A treatment being outside a medicine's licensed indication does not automatically mean it cannot be prescribed. Licensed medicines can sometimes be prescribed off-label when a clinician considers this appropriate for an individual patient, based on clinical judgement, available evidence and relevant professional guidance.

Four ways this evidence gets misread

Attributing findings to the wrong medicine. The kidney trial and the phase 3 liver evidence are semaglutide trials. They are routinely described as applying to the whole class.

Ignoring the population. SELECT studied people with established cardiovascular disease. FLOW studied people with diabetes and chronic kidney disease. SUMMIT studied people with obesity and a specific type of heart failure. None of these describes a healthy person taking treatment for weight alone.

Treating non-inferiority as protection. SURPASS-CVOT compared tirzepatide with another active medicine. Not worse than an established treatment is a different claim from protecting your heart.

Reading relative risk as personal certainty. A 20% relative reduction in a trial population does not mean a 20% reduction in your personal risk, which depends on what your risk was to begin with.

What you can reasonably expect

For most people taking these medicines for weight management, the realistic expectation is the one supported across the whole field: that losing weight and keeping it off improves blood pressure, blood glucose, blood fats and liver fat, and that those improvements are worth having in their own right.

Two caveats are worth holding onto.

The improvements track the weight loss. When weight returns, the cardiometabolic improvements largely revert. This was seen clearly in follow-up after treatment stopped in earlier semaglutide research.

Body composition affects the outcome. Weight lost includes muscle as well as fat. Protein intake and resistance activity influence how much, and muscle matters for metabolic health as well as strength.

When to seek advice

Speak to your prescriber or a healthcare professional if:

• You have cardiovascular disease, kidney disease or liver disease and are considering weight management treatment, especially if you also have metabolic syndrome or other risk factors that may need closer review
• You take medicines for blood pressure, heart conditions or diabetes, which may need reviewing as your weight or blood glucose changes.
• You have been told you have raised liver enzymes or fatty liver disease / NAFLD, as blood tests or liver function tests may be needed where clinically indicated
• Common metabolic risk factors apply, including high blood pressure, abnormal lipids, insulin resistance, and excess weight
• Your blood pressure or blood glucose changes noticeably during treatment

Seek urgent medical attention for chest pain, severe breathlessness, severe and persistent stomach pain that may spread through to your back, swelling of the face, lips, tongue or throat, dark urine, or signs of significant dehydration.

The useful takeaway

If you are considering treatment, the organ health evidence is a reason to take the wider health picture seriously, not a reason to expect a specific protective effect.

The practical version is simple. Get your blood pressure, blood glucose and cholesterol checked, discuss any existing heart, kidney or liver condition with a clinician who can see your full history, and treat the weight as one part of that conversation rather than the whole of it. The numbers worth tracking during treatment are rarely the one on the scales.

Medical Disclaimer

This article is for general information only. It is not medical advice and it does not replace an individual assessment by an appropriately qualified healthcare professional.

Semaglutide and tirzepatide products have different UK licensed indications. Both are licensed for weight management in adults meeting specified criteria, and for type 2 diabetes in relevant formulations. Wegovy (semaglutide) is also licensed to reduce the risk of major adverse cardiovascular events in certain adults with established cardiovascular disease and overweight or obesity. Neither medicine is currently licensed specifically for chronic kidney disease or liver disease.

Existing heart, kidney or liver conditions require their own assessment and management. Do not start, stop or change any prescribed medicine without advice.

Seek urgent medical attention for chest pain, severe breathlessness, severe and persistent stomach pain that may spread to your back, swelling of the face, lips, tongue or throat, or signs of significant dehydration.